Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.83 |
| ▸ | CACNA1S known ✓ | Q13698 | 10/20 | 0.81 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.81 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.81 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.81 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.81 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.81 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.81 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.81 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.81 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.81 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.81 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.81 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.81 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.81 |
| ▸ | SCN11A known ✓ | Q9UI33 | 1/20 | 0.81 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.81 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16588915 | 1.00 | CYP3A4 (0.83) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL12557663 | 0.99 | CACNA1S (0.82) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL10330283 | 0.99 | CACNA1S (0.82) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| Hydrochloric Acid SCHEMBL9505932 | 0.94 | LMNA (0.74) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL19449326 | 0.92 | CACNA1S (0.72) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL9505934 | 0.92 | CACNA1S (0.84) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL22512416 | 0.92 | CACNA1S (0.84) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL22269192 | 0.91 | CACNA1S (0.82) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL13273508 | 0.91 | CACNA1S (0.82) | CYP3A4ABCB11LMNAKCNH2MEN1 | |
| SCHEMBL19568199 | 0.91 | CACNA1S (0.82) | CYP3A4ABCB11LMNAKCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993558-B2 | Compositions comprising a calcium channel blocker or a calmodulin blocker for use in the removal of hyperplastic skin lesions | Dr. Kenneth Adams Medicine Professional Corporation (CA) | 2015-03-31 | — | — | US | disclosed |
| EP-0279425-B1 | USE OF BENZOTHIAZEPINE DERIVATIVES, IN PARTICULAR DILTIAZEM, IN THE MANUFACTURE OF MEDICAMENTS TO PROTECT LYMPHOCYTES | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1993-08-04 | — | — | EP | disclosed |
| US-4861770-A | Use of benzothiazepine derivatives as lymphocyte protectors | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | disclosed |
| EP-0279425-A2 | Use of benzothiazepine derivatives, in particular diltiazem, in the manufacture of medicaments to protect lymphocytes | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1988-08-24 | — | — | EP | disclosed |